

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 84849

Title: Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: two cases report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05480683

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Fellow, Academic Research, Adjunct Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2023-03-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-03-30 08:38

Reviewer performed review: 2023-04-09 16:18

Review time: 10 Days and 7 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Journal – World Journal of Clinical Cases Manuscript Information Manuscript ID: 84849 Type research article Title. Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: case report and literature review Main comment. The work is well written and well conducted. Cases are well described. I recommend this manuscript for publication in World Journal of Clinical Cases. Minor comments: 1. Authors are kindly encouraged to include the following references on the role of PD-1/PD-L1 inhibitors in gastric cancer: a. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10605-y

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801892/

b.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724489/ 2. The combined therapy with checkpoint inhibitors with additional antitumor-drugs such as histone deacetylase inhibitors (PD-1/PD-L1 inhibitors), have repeatedly been proposed in cancers (PMID: 35350569 and PMID: 33564072), including gastric cancer PMID: 35008230. This is an important information that should be included in the manuscript alongside the three aforementioned supporting references 3. The staining in fig 1, panel C



should be explained in the caption. Is that a specific gastric cancer marker? Or a HE magnification? 4. Figures' captions should be in text format 5. A brief introduction of both cases should be provided before detailed cases presentation 6. "discuss! Should be "discussion" 7. Please check the abbreviations such as OS and DFS which should be explained the first time being mentioned



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 84849

Title: Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: two cases report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00503228

Position: Editorial Board

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2023-03-30

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-19 02:39

Reviewer performed review: 2023-05-19 10:45

Review time: 8 Hours

	[] Grade A: Excellent [] Grade B: Very good [] Grade C:
Scientific quality	Good
	[Y] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Interesting cases but I doubt you may call them rare cases for reporting. There are also some limitations in your approach. Your TNM staging is controversial since both the patients showed positive results in laparoscopic comprehensive exploration and peritoneal lavage for tumor cells, post neoadjuvant therapy that should have been considered distant metastasis and stage IV disease. Moreover, one of the patients was also positive for signet ring cells indicating very poor prognosis. Although there is controversy in the treatment of patients with advanced gastric cancer as your patients, but cytoreduction therapy and intraperitoneal hyperthermic chemoperfusion have been used with some promising results. But local therapy and operation is not recommended. Putting together, recurrence of the cancer especially in the intraperitoneal organs was not unexpected, but rather very expected event in your patients. Moreover, although PD-1 inhibitors have been recommended in patients with metastatic gastric cancer, you've used PD-1 inhibitor Camrelizumab as a neoadjuvant therapy regimen, which is not recommended. Moreover, testing for Her2-NEU was also recommended for targeted therapy.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 84849

Title: Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: two cases report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00183279

Position: Editorial Board

Academic degree: FRCS (Ed), MD, MS

Professional title: Professor

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2023-03-30

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-12 16:09

Reviewer performed review: 2023-06-23 11:50

Review time: 10 Days and 19 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [] Anonymous [Y] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors are presenting a case of Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy. Gastric cancer ranks amongst top most cancer worldwide. Usual treatment for locally advanced GC(Neoadjuvant chemo and surgery)have shown little benefit in terms of long term results. The sandwich therapy results are little better. The authors are touching the subject of Neoadjuvant and the combination of immunotherapy. This is a very exciting and promising field and also the value of ypCR. Unfortunately the presentation is very confusing with grammatic errors and also unnecessary text. I suggest , the authors may present this as a short report or a letter to the editor. But before that, the article needs to be rewritten in concise and meaningful way.